Learn about our AAV gene therapy clinical trials

While we help raise awareness of clinical research opportunities, enrolling physicians are responsible for screening potential patients and confirming their eligibility. Eligibility criteria, based on pre-determined requirements related to the disease and the patient’s medical history, are described in the ClinicalTrials.gov study postings. These criteria allow us to conduct studies as safely as possible and control for health and disease factors that make it easier to compare results across study participants. 

Participants may be ineligible if their immune systems have existing antibodies or neutralizing antibodies (NAbs) that will likely destroy the gene therapy before it can do its job. People who are treated with most gene therapies will develop NAbs, which currently prevent re-dosing with the gene. These are challenges that AskBio is actively working to overcome.  

Read more about our redosing and NAb research initiatives with Selecta Biosciences.

Clinical Trial: Late-Onset Pompe Disease

Status: Active, Not Recruiting

More information

Clinical Trial: Congestive Heart Failure

Status: Enrolling

More information

Clinical Trial: Multiple System Atrophy

Status: Enrolling

More information

Clinical Trial: Parkinson’s Disease

Status: Active, Not Recruiting

More information

Clinical Trial: LGMD 2I/R9

Status: Enrolling

Expanded Access

We are committed to making all approved therapies widely available as rapidly as possible; however, it is too early at this time to consider plans for expanded access. When we have published results from a controlled clinical trial that suggest a therapy may provide benefit for patients with acceptable safety, we will consider options such as expanded access.

Read more about our expanded access policy.

Gene therapy clinical trials

Gene therapy clinical trial design varies depending on the disease, its prevalence and orphan disease classification, the type of therapy, and the number of participants. To bring these medicines to patients as efficiently and safely as possible, gene therapy trials often combine early- and late-phase processes and involve a small number of patients.  At present, gene therapy is a one-time treatment. Individuals are dosed then followed for three to five years to assess the long-term safety and overall impact on their health. 

In rare diseases, patients often do not live close to medical centers of excellence. As such, AskBio will help arrange and pay for their travel and design studies that allow for many assessments to occur at home.

Clinical trial process from research collaborators to clinical results

Patient-centered approach

Our patients are our most important collaborators in the assessment of new treatments for serious diseases. As such, their safety is the first priority in all studies.

We believe our commitment to patients is best served by carefully designing our studies to maximize safety and decrease time to market. We accomplish this by:

  • Building modern study design to include all available regulatory precedence and data to improve outcomes
  • Developing explicit trial protocols that include input from scientific, patient, and medical community collaborators
  • Clearly articulating study requirements to accelerate participant recruiting and ensure participants are well-informed
  • Closely collaborating with the FDA and other regulatory agencies to ensure compliance with all reporting requirements

We are committed to publishing the results of all of our clinical studies to advance the field of genetic research and the development of any therapeutics that will benefit patients.

AskBio pipeline

The AskBio pipeline

Our pipeline is the direct result of listening to patients, their families, their care teams, and patient advocacy organizations. 

View our pipeline »

Patient advocacy partners

We have a deep history of partnering with advocacy groups dating back to 2001 when AskBio began as a result of the first-ever research grant to a for-profit entity by the Muscular Dystrophy Association.